Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
June 14 2024 - 9:00AM
Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a
pioneering force in medical aesthetics, announced the formation of
a new Scientific Advisory Board to support the advancement of
EL-22, a first-in-class engineered probiotic approach, to address
obesity’s pressing issue of preserving muscle while on weight loss
treatments, including GLP-1 receptor agonists.
“We are honored to be forming a Scientific
Advisory Board with renowned members that possess deep and
complementary knowledge in metabolic diseases, obesity, weight
management, muscle preservation and physical function in addition
to significant experience in clinical research and drug
development,” said Dr. Jordan R. Plews, PhD, Chief Executive
Officer of Elevai. “These experts will help us to gain knowledge
about the latest advancements and assist in our vision to develop
our lead clinical candidate EL-22 as a differentiated, oral
myostatin approach that may play an important role in addressing
the unmet medical need of obese patients, who need to preserve
muscle while losing weight.”
The members of Elevai’s new Scientific Advisory
Board include:
Roger A. Fielding, PhD
Roger A. Fielding, PhD serves as Team Lead
and Senior Scientist of the Nutrition, Exercise Physiology, and
Sarcopenia (NEPS) Team at the Jean Mayer USDA Human Nutrition
Research Center on Aging at Tufts University. He is also Professor
of Nutrition at Tufts’ Friedman School of Nutrition Science and
Policy, Professor of Medicine at Tufts University School of
Medicine and the Associate Director of the Boston Claude D. Pepper
Older Americans Independence Center. Dr. Fielding is an
internationally known researcher who studies the underlying
mechanisms contributing to age-associated decline in skeletal
muscle mass, the resultant impact on function, and the potential
role of exercise, nutrition, physical activity and other therapies
on attenuating this process. He has published over 300
peer-reviewed papers (H-index 115). Dr. Fielding has a strong
record of extramural funding, including support from the NIH, USDA,
foundations and industry. He is a Deputy Editor of The Journals of
Gerontology Medical Sciences, and Calcified Tissues International
and Musculoskeletal Research. He has also served as a
reviewer on numerous National Institutes of Health (NIH) study
sections and was elected to the NIH/CSR College of Reviewers. In
2015, Dr. Fielding received the Olof Johnell Science Award from the
International Osteoporosis Foundation, and in 2021 he received the
Herbert Fleisch Medal from the same organization.
Eduardo Grunvald, MD, FACP
Eduardo Grunvald, MD, is a board-certified
obesity medicine physician. As Director of the Weight Management
Program of the University of California San Diego, Dr. Grunvald
evaluates and manages patients through their health- and
weight-loss journeys and has extensive experience using medications
for weight management. As a professor in the Department of
Medicine, Dr. Grunvald is very active in teaching on topics such as
metabolism, weight regulation and the treatment of obesity and
weight-related medical conditions. He serves on a national
committee working on standardizing obesity education in medical
schools. His research interests include anti-obesity medications,
obesity medicine education and bariatric surgery. Dr. Grunvald
completed his residency training at the UC San Diego School of
Medicine. Dr. Grunvald has served as an advisory board consultant
for Novo Nordisk. He earned his medical degree at the University of
Washington School of Medicine. He is board certified in internal
medicine and obesity medicine, and is a fellow of the American
College of Physicians (FACP).
Elevai expects to be recruiting additional
distinguished scientific leaders with vast experience in the
metabolic and obesity field to join its the Scientific Advisory
Board.
About Elevai Labs, Inc.Elevai
Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and
biopharmaceutical drug development, focusing on innovations for
skin aesthetics and treatments tied to obesity and metabolic
health. Driven by a commitment to scientific research, we aim to
transform personal health and beauty. For more information, please
visit www.elevailabs.com.
About Elevai BiosciencesElevai
Biosciences Inc., an Elevai Labs company, is a biopharmaceutical
company focusing on the development and acquisition of cutting-edge
aesthetic medicines. Our lead asset, EL-22, is leveraging a
first-in-class engineered probiotic approach to address obesity’s
pressing issue of preserving muscle while on weight loss
treatments, including GLP-1 receptor agonists. For more
information, please visit www.elevaibio.com.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Words such as
“believes,” “expects,” “plans,” “potential,” “would” and “future”
or similar expressions such as “look forward” are intended to
identify forward-looking statements. Although the Company believes
that the expectations expressed in these forward-looking statements
are reasonable, it cannot assure you that such expectations will
turn out to be correct, and the Company cautions investors that
actual results may differ materially from the anticipated results.
These and other risks are described more fully in Elevai’s filings
with the Securities and Exchange Commission (“SEC”), including the
“Risk Factors” section of the Company’s Annual Report on Form 10-K
for the year ended December 31, 2023, filed with the SEC on March
29, 2024, and its other documents subsequently filed with or
furnished to the SEC. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Except to the extent required by law, the Company undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were
made.
These and other risks are described more fully
in Elevai’s filings with the Securities and Exchange Commission
(“SEC”), including the “Risk Factors” section of the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023,
filed with the SEC on March 29, 2024, and its other documents
subsequently filed with or furnished to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, the Company undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
Investor Relations Contact:Tyler Troup,
Circadian Group IRIR@elevailabs.com
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Jul 2023 to Jul 2024